Skip to main content

Market Overview

Charles River Laboratories, AstraZeneca Renew Strategic Partnership Agreement


Charles River Laboratories International, Inc. (NYSE: CRL) today
announced that it has extended its initial three-year partnership with
AstraZeneca (NYSE: AZN) for an additional five-year period. Under the
agreement, which extends into 2020, Charles River retains its position
as AstraZeneca's preferred strategic partner for outsourced regulated
safety assessment and development DMPK (drug metabolism and

James C. Foster, Chairman, President and Chief Executive Officer of
Charles River said, "We are extremely pleased that AstraZeneca has
chosen to extend its relationship with Charles River. Our combined
scientific expertise has been pivotal to enabling AstraZeneca to create
a flexible research platform to deliver innovative health solutions. We
are proud of the

See full press release


Related Articles (CRL)

View Comments and Join the Discussion!

Posted-In: News Contracts Press Releases

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at